HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance

November 6, 2023 4:05 PM EST

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65.... More